Changes in a growth hormone-related factor didn't match changes in muscle density or size in people with HIV and belly fat taking tesamorelin.

Scientific Claim

No significant correlation was found between changes in insulin-like growth factor-1 levels and changes in muscle density or area in tesamorelin responders with HIV and abdominal obesity.

Original Statement

“Change in IGF-1 was not significantly correlated with change in density or area.”

From study:The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

association

Can only show association/correlation

Assessment Explanation

The claim accurately describes the null correlation result using 'no significant correlation' which matches the study's statistical analysis.

Evidence from Studies

Supporting (1)

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Randomized Controlled Trial

Human

2019

Contradicting (0)

No contradicting evidence found

Source Study

The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV

Score: 60

DOI: 10.14283/jfa.2018.45

Similar Assertions

In people with HIV and belly fat who responded to tesamorelin, muscle density changes were linked to belly fat loss but not to changes in a growth-related hormone.

93%

For people with HIV taking tesamorelin, changes in their growth hormone levels didn't match changes in their trunk muscle thickness or size.

93%

Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, but this effect was reduced when considering changes in a growth hormone-related factor.

91%

People with HIV who have belly fat and are on medication to control the virus who took tesamorelin had higher levels of a growth-related hormone called IGF-1. This finding is from the abstract summary - full study details were not available

90%

The muscle growth from this drug wasn’t because belly fat went down—it was more likely due to a rise in a growth-related hormone called IGF-1.

89%